|
|
|
|
Direct Cost |
Indirect Cost |
|
1R01AI143931-01A1 |
Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$250,000 |
$193,750 |
$443,750 |
1R01AI150381-01A1 |
CAR T CELLS ENGINEERED TO KILL HIV-INFECTED CELLS WHILE SECRETING BROADLY NEUTRALIZING ANTIBODIES |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$250,000 |
$193,750 |
$443,750 |
1R01AI152523-01 |
Expediting elicitation of HIV-1 bnAbs with membrane Env vaccines |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$526,428 |
$199,801 |
$726,229 |
1R01AI153298-01 |
Covalent Inhibition as a Method to Counteract Botulinum Intoxication |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$451,964 |
$240,703 |
$692,667 |
1R21AI144232-01A1 |
Rheumatoid factor and cryoglobulinemia in chronic viral infection |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$150,000 |
$140,250 |
$290,250 |
1R21AI150346-01A1 |
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$150,000 |
$116,250 |
$266,250 |
1R21AI154471-01 |
AIM2 as a negative regulator of renal ischemia/reperfusion injury |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$150,000 |
$116,250 |
$266,250 |
1R56AI149004-01A1 |
Spread and Evolution of West Nile virus in the United States |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$648,649 |
$263,085 |
$911,734 |
1U01AI151812-01 |
West African Emerging Infectious Disease Research Center (WA-EIDRC) |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$1,534,498 |
$348,725 |
$1,883,223 |
2R01AI114730-06 |
Influenza virus receptors on human airway epithelial cells |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$399,300 |
$224,750 |
$624,050 |
2R56AI113867-06 |
Glycan dependent epitopes of HIV broadly neutralizing antibodies |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$499,999 |
$387,499 |
$887,498 |
3F31AI131873-03S1 |
Broadening autologous Tier 2 anti-HIV neutralizing antibodies |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$492 |
|
$492 |
3U19AI100627-08S1 |
Systems Approach to Immunity and Inflammation |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$300,501 |
$66,096 |
$366,597 |
3U19AI100627-09S1 |
Systems Approach to Immunity and Inflammation |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$674,874 |
$163,708 |
$838,582 |
3U19AI135995-03S1 |
Consortium for Viral Systems Biology (CViSB) |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$525,885 |
$96,880 |
$622,765 |
3U19AI135995-03S2 |
Consortium for Viral Systems Biology (CViSB) |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$140,845 |
$109,155 |
$250,000 |
3UM1AI144462-01S2 |
Consortium for HIV/AIDS Vaccine Development |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$127,963 |
$60,751 |
$188,714 |
3UM1AI144462-02S1 |
Consortium for HIV/AIDS Vaccine Development |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$653,865 |
$163,004 |
$816,869 |
5F30AI136646-03 |
Lymph node-targeted delivery of HIV vaccine candidates |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$32,520 |
|
$32,520 |
5K99AI139445-02 |
Mechanistic understanding of influenza-host interactions from a zoonotic perspective |
SCRIPPS RESEARCH INSTITUTE |
NIAID |
$30,582 |
$2,447 |
$33,029 |